biotech · Ovarian Clear Cell Carcinoma · Tumors · LIXT
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
LIXTE BIOTECHNOLOGY HOLDINGS drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
LIXTE BIOTECHNOLOGY HOLDINGS drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Antineoplastic and immunomodulating agents (L01) compound in LIXTE BIOTECHNOLOGY HOLDINGS's portfolio. Molecular target: Programmed cell death protein 1.
US regulatory status: approved. Molecular target: Programmed cell death protein 1.
Development asset linked to LIXTE BIOTECHNOLOGY HOLDINGS in public FDA and regional records.